vs
Side-by-side financial comparison of Stoke Therapeutics, Inc. (STOK) and Xometry, Inc. (XMTR). Click either name above to swap in a different company.
Xometry, Inc. is the larger business by last-quarter revenue ($192.4M vs $158.6M, roughly 1.2× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -4.5%, a 75.7% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 29.5%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $-5.9M).
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
Xometry is an online marketplace for sourcing on-demand manufactured parts for prototyping and large-scale production.
STOK vs XMTR — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $158.6M | $192.4M |
| Net Profit | $112.9M | $-8.6M |
| Gross Margin | — | 39.1% |
| Operating Margin | 70.2% | -4.6% |
| Net Margin | 71.2% | -4.5% |
| Revenue YoY | 3661.1% | 29.5% |
| Net Profit YoY | 528.0% | 12.7% |
| EPS (diluted) | $1.90 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $192.4M | ||
| Q3 25 | — | $180.7M | ||
| Q2 25 | — | $162.5M | ||
| Q1 25 | $158.6M | $151.0M | ||
| Q4 24 | $22.6M | $148.5M | ||
| Q3 24 | — | $141.7M | ||
| Q2 24 | — | $132.6M | ||
| Q1 24 | — | $122.7M |
| Q4 25 | — | $-8.6M | ||
| Q3 25 | — | $-11.6M | ||
| Q2 25 | — | $-26.4M | ||
| Q1 25 | $112.9M | $-15.1M | ||
| Q4 24 | $-10.5M | $-9.9M | ||
| Q3 24 | — | $-10.2M | ||
| Q2 24 | — | $-13.7M | ||
| Q1 24 | — | $-16.6M |
| Q4 25 | — | 39.1% | ||
| Q3 25 | — | 39.9% | ||
| Q2 25 | — | 40.1% | ||
| Q1 25 | — | 37.3% | ||
| Q4 24 | — | 39.7% | ||
| Q3 24 | — | 39.4% | ||
| Q2 24 | — | 39.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | — | -4.6% | ||
| Q3 25 | — | -6.1% | ||
| Q2 25 | — | -6.3% | ||
| Q1 25 | 70.2% | -10.2% | ||
| Q4 24 | -60.4% | -7.8% | ||
| Q3 24 | — | -8.1% | ||
| Q2 24 | — | -11.5% | ||
| Q1 24 | — | -14.6% |
| Q4 25 | — | -4.5% | ||
| Q3 25 | — | -6.4% | ||
| Q2 25 | — | -16.3% | ||
| Q1 25 | 71.2% | -10.0% | ||
| Q4 24 | -46.4% | -6.7% | ||
| Q3 24 | — | -7.2% | ||
| Q2 24 | — | -10.3% | ||
| Q1 24 | — | -13.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $1.90 | — | ||
| Q4 24 | $-0.15 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $274.8M | $219.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $350.1M | $275.6M |
| Total Assets | $406.9M | $703.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $219.1M | ||
| Q3 25 | — | $224.5M | ||
| Q2 25 | — | $225.8M | ||
| Q1 25 | $274.8M | $231.4M | ||
| Q4 24 | $128.0M | $239.8M | ||
| Q3 24 | — | $234.0M | ||
| Q2 24 | — | $240.9M | ||
| Q1 24 | — | $253.8M |
| Q4 25 | — | $275.6M | ||
| Q3 25 | — | $272.0M | ||
| Q2 25 | — | $270.4M | ||
| Q1 25 | $350.1M | $309.9M | ||
| Q4 24 | $229.0M | $314.5M | ||
| Q3 24 | — | $315.2M | ||
| Q2 24 | — | $315.8M | ||
| Q1 24 | — | $320.4M |
| Q4 25 | — | $703.7M | ||
| Q3 25 | — | $698.9M | ||
| Q2 25 | — | $687.0M | ||
| Q1 25 | $406.9M | $690.1M | ||
| Q4 24 | $271.6M | $680.1M | ||
| Q3 24 | — | $678.2M | ||
| Q2 24 | — | $678.6M | ||
| Q1 24 | — | $692.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $131.8M | $4.4M |
| Free Cash FlowOCF − Capex | $131.7M | $-5.9M |
| FCF MarginFCF / Revenue | 83.0% | -3.0% |
| Capex IntensityCapex / Revenue | 0.1% | 5.3% |
| Cash ConversionOCF / Net Profit | 1.17× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-24.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.4M | ||
| Q3 25 | — | $5.8M | ||
| Q2 25 | — | $-427.0K | ||
| Q1 25 | $131.8M | $-3.7M | ||
| Q4 24 | $-23.2M | $9.1M | ||
| Q3 24 | — | $-3.6M | ||
| Q2 24 | — | $-9.1M | ||
| Q1 24 | — | $-11.7M |
| Q4 25 | — | $-5.9M | ||
| Q3 25 | — | $-1.7M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | $131.7M | $-9.2M | ||
| Q4 24 | $-23.2M | $4.5M | ||
| Q3 24 | — | $-8.4M | ||
| Q2 24 | — | $-13.5M | ||
| Q1 24 | — | $-16.1M |
| Q4 25 | — | -3.0% | ||
| Q3 25 | — | -0.9% | ||
| Q2 25 | — | -4.5% | ||
| Q1 25 | 83.0% | -6.1% | ||
| Q4 24 | -102.7% | 3.1% | ||
| Q3 24 | — | -6.0% | ||
| Q2 24 | — | -10.2% | ||
| Q1 24 | — | -13.1% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 4.1% | ||
| Q2 25 | — | 4.3% | ||
| Q1 25 | 0.1% | 3.6% | ||
| Q4 24 | 0.2% | 3.1% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 3.3% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.17× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
STOK
Segment breakdown not available.
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
